Brief: Sosei Says Co & Neurocrine Biosciences Confirms Plans To Evaluate 2 New Muscarinic Agonist Candidates In Phase 1 Clinical Studies
06/12/2023 08:13
Dec 6 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI HEPTARES’ PARTNER NEUROCRINE BIOSCIENCES CONFIRMS
ITS
PLANS TO EVALUATE TWO NEW MUSCARINIC AGONIST CANDIDATES IN PHASE
1 CLINICAL STUDIES
* SOSEI - SOSEI HEPTARES' PARTNER NEUROCRINE BIOSCIENCES
CONFIRMS
ITS PLANS TO EVALUATE TWO NEW MUSCARINIC AGONIST CANDIDATES IN
PHASE 1 CLINICAL STUDIES
Source text for Eikon: ID:nGNX1CjT2Q
Further company coverage: 4565.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up